Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
preEMBER
NCT07287098Phase 2Recruiting
- Sponsor
- Eli Lilly and Company
- Start
- May 2026
- Primary completion
- Jan 2029
- Modality
- Small Molecules
- Countries
- 7
01
Overview
A Phase 2 trial of imlunestrant in breast cancer, sponsored by Eli Lilly and Company. Started May 2026; status: recruiting.
02
Drugs
imlunestrant
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT07287098.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07287098.